Arpraziquantel
{{Short description|Medication}}
{{Use American English|date=December 2023}}
{{Use dmy dates|date=December 2023}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| image = (R)-Praziquantel.svg
| width =
| alt =
| caption =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration =
| class = Anthelmintic
| ATCvet =
| ATC_prefix = P02
| ATC_suffix = BA03
| ATC_supplemental =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 57452-98-9
| CAS_supplemental =
| PubChem = 445900
| IUPHAR_ligand =
| DrugBank = DB11749
| ChemSpiderID = 393394
| UNII = WF15T5925V
| KEGG = D12741
| ChEBI =
| ChEMBL = 1235551
| NIAID_ChemDB =
| PDB_ligand = PZQ
| synonyms = (R)-Praziquantel
| IUPAC_name =
| C = 19 | H = 24 | N = 2 | O = 2
| SMILES = [H][C@@]12CN(CC(=O)N1CCC1=CC=CC=C21)C(=O)C1CCCCC1
| StdInChI = 1S/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13H2/t17-/m0/s1
| StdInChI_comment =
| StdInChIKey = FSVJFNAIGNNGKK-KRWDZBQOSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
Arpraziquantel ((R)-praziquantel) is the eutomer (the biologically active enantiomer) of praziquantel, and is a medication which is currently under investigation for the treatment of schistosomiasis in young children since it has less side effects than the usual racemic mixture formulation of praziquantel.
Society and culture
= Legal status =
In December 2023, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion in accordance with Article 58 of Regulation (EC) No 726/20041 for the medicinal product arpraziquantel, intended for the treatment of schistosomiasis in young children. The applicant for this medicinal product is Merck Europe B.V. It is intended exclusively for markets outside the European Union.{{cite web | website=European Medicines Agency | title=Arpraziquantel | date=14 December 2023 | url=https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/arpraziquantel | access-date=20 December 2023 | archive-date=20 December 2023 | archive-url=https://web.archive.org/web/20231220045146/https://www.ema.europa.eu/en/opinion-medicine-use-outside-EU/human/arpraziquantel | url-status=live }} Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
= Names =
Arpraziquantel is the International nonproprietary name.{{cite journal | vauthors = ((World Health Organization)) | year = 2020 | title = International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83 | journal = WHO Drug Information | volume = 34 | issue = 1 | hdl = 10665/339768 | hdl-access = free | author-link = World Health Organization }}
References
{{reflist}}
Further reading
- {{cite journal | vauthors = Zdesenko G, Mutapi F | title = Drug metabolism and pharmacokinetics of praziquantel: A review of variable drug exposure during schistosomiasis treatment in human hosts and experimental models | journal = PLOS Neglected Tropical Diseases | volume = 14 | issue = 9 | pages = e0008649 | date = September 2020 | pmid = 32976496 | pmc = 7518612 | doi = 10.1371/journal.pntd.0008649 | doi-access = free }}
{{Anthelmintics}}
{{Portal bar | Medicine}}
{{Authority control}}